Axpaxli Could Transform Wet AMD Care

Retina Conversations: Ocular Therapeutics head Pravin U. Dugel, MD, explains SOL-1 trial results and how Axpaxli could reshape wet AMD treatment.

By: Pravin U. Dugel, MD

Retinal Physician February 27, 2026

5 Key Takeaways

1

Axpaxli outperformed an FDA-approved anti-VEGF therapy in the phase 3 SOL-1 trial for wet age-related macular degeneration.
2

The drug is a bioresorbable hydrogel containing axitinib, a tyrosine kinase inhibitor with antiangiogenic properties.
3

SOL-1 is the first superiority trial in the field to succeed, potentially leading to the first superiority label for a wet AMD treatment.
4

Ocular Therapeutix plans to file for approval based solely on the SOL-1 trial results, following FDA guidelines and receiving a special protocol agreement.
5

The ongoing SOL-R trial will provide additional information but is not deemed necessary for Axpaxli's approval.

Pravin U. Dugel

Executive Chairman, President, and CEO

Affiliations: Ocular Therapeutix

Bio: Dr. Dugel discussed Ocular Therapeutix’s phase 3 SOL-1 trial results for Axpaxli (OTX-TKI), a bioresorbable intravitreal hydrogel incorporating axitinib, as well as the company’s SOL-R trial and regulatory strategy. His comments addressed how Axpaxli could change the treatment paradigm for wet AMD care.

PentaVision

Retinal Physician

Axpaxli Could Transform Wet AMD Care

5 Key Takeaways

1

2

3

4

5

Recommendations